Highlights: U.S. FDA lifts the Clinical Hold on NUZ‑001, Neurizon®'s lead investigational therapy for ALS Clears the way for entry into the HEALEY ALS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback